Massachusetts Financial Services Co. MA Purchases 4,918 Shares of Hologic, Inc. (NASDAQ:HOLX)

Massachusetts Financial Services Co. MA grew its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 11.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 49,209 shares of the medical equipment provider's stock after acquiring an additional 4,918 shares during the quarter. Massachusetts Financial Services Co. MA's holdings in Hologic were worth $3,040,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in HOLX. Norges Bank purchased a new stake in shares of Hologic during the fourth quarter worth about $133,414,000. Champlain Investment Partners LLC acquired a new position in Hologic during the 4th quarter valued at approximately $79,291,000. Redwood Wealth Management Group LLC acquired a new stake in shares of Hologic during the first quarter worth $3,534,000. Northern Trust Corp increased its holdings in Hologic by 26.9% in the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock worth $226,898,000 after buying an additional 668,086 shares during the period. Finally, Invesco Ltd. raised its stake in shares of Hologic by 16.4% during the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock valued at $293,434,000 after buying an additional 572,187 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Hologic Stock Up 2.5%

Hologic stock traded up $1.58 during midday trading on Tuesday, hitting $65.27. 742,616 shares of the company were exchanged, compared to its average volume of 2,379,402. The company's fifty day moving average price is $62.46 and its 200-day moving average price is $63.12. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.24 and a quick ratio of 2.52. The company has a market cap of $14.54 billion, a PE ratio of 27.53, a price-to-earnings-growth ratio of 2.35 and a beta of 0.55. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The firm's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.03 earnings per share. On average, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

HOLX has been the subject of several research analyst reports. Raymond James Financial restated an "outperform" rating and set a $71.00 price target (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $60.00 to $80.00 in a research report on Wednesday, July 9th. Evercore ISI raised their price objective on shares of Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Stephens dropped their price objective on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Finally, Royal Bank Of Canada dropped their price target on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Hologic presently has a consensus rating of "Hold" and a consensus target price of $77.33.

Insiders Place Their Bets

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of Hologic stock in a transaction that occurred on Wednesday, May 7th. The stock was acquired at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the acquisition, the director owned 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.88% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.